Blood Biomarker Optimization

TL;DR

Six circulating biomarkers are the most actionable modifiable targets for cardiometabolic longevity: ApoB (atherogenic particle count), hs-CRP (chronic inflammation), fasting insulin (insulin resistance), TG:HDL ratio (atherogenic dyslipidemia), HbA1c (glycemic exposure and advanced glycation), and iron metabolism (ferritin and transferrin saturation). All six have prospective evidence linking them to hard endpoints: myocardial infarction, stroke, type 2 diabetes, and all-cause mortality. They are dynamic and responsive to intervention — making them the most actionable domain in longevity medicine.

Why It Matters for Vitals

Blood biomarkers are the closest thing to a real-time feedback loop for longevity interventions. Unlike wearable signals (HRV, RHR) which reflect autonomic state on a minute-to-minute basis, blood biomarkers reflect the underlying biological environment that drives long-term health trajectories. Vitals users on Retatrutide, GHK-Cu, or exercise programs should use these biomarkers to verify that stack changes are producing measurable physiological change.

Core Biomarker Reference Table

Biomarker	Standard Reference Range	Optimal Longevity Target	Units
ApoB	60–140	< 70 (very high-risk: < 50)	mg/dL
hs-CRP	< 3.0	< 1.0; aim < 0.5 if achievable	mg/L
Fasting Insulin	2.6–24.9	3.0–6.0 (ideal: < 5)	μIU/mL
TG:HDL Ratio	< 2.5 (men), < 1.5 (women)	< 2.0 (men), < 1.3 (women)	ratio
HbA1c	4.0–5.6 (normal); 5.7–6.4 (prediabetes)	5.0–5.4 (38–41 mmol/mol)	%
Ferritin	20–250 (women), 30–400 (men)	50–150 (both sexes); avoid > 300	ng/mL
TSAT	20–50%	25–35% (mid-range); avoid > 45%	%

Key Biomarkers Explained

ApoB — Atherogenic Particle Count

ApoB is the structural protein of all atherogenic lipoproteins (LDL, VLDL, IDL, lipoprotein(a)). Each particle contains exactly one ApoB molecule — making ApoB a direct count of circulating atherogenic particle number, superior to LDL-C which measures cholesterol content regardless of particle count.

Why ApoB > LDL-C: Insulin resistance increases VLDL production → elevates ApoB even when LDL-C appears “normal.” ApoB/LDL-C ratio > 0.6 suggests small dense LDL particles (pattern B) — independently atherogenic even when LDL-C looks deceptively normal.

Key evidence: Mendelian randomization + INTERHEART — each 10 mg/dL ApoB lowering sustained over a lifetime → ~50% proportional coronary risk reduction (Ference et al., EHJ, PMID 20031900).

hs-CRP — Chronic Inflammation

hs-CRP is produced by hepatocytes in response to IL-6 and TNF-α. The JUPITER trial established hs-CRP as a causally relevant cardiovascular target — rosuvastatin benefited patients with normal LDL but elevated hs-CRP, independent of LDL lowering. hs-CRP is not merely a bystander: it promotes complement activation, facilitates LDL oxidation, and impairs endothelial nitric oxide production.

Note: hs-CRP is acute-phase reactive — any acute infection or injury elevates it transiently. Measure when clinically stable; average two measurements ≥ 2 weeks apart.

Fasting Insulin

Fasting insulin is the single most sensitive marker of insulin resistance, elevating years before fasting glucose becomes abnormal. Elevated fasting insulin drives:

• Hepatic VLDL overproduction → elevates triglycerides and ApoB
• mTORC1 activation → inhibits autophagy (see Autophagy)
• Smooth muscle cell proliferation in vessel walls
• Visceral fat accumulation (cortisol-like effect)

HOMA-IR (fasting glucose × fasting insulin / 405) quantifies insulin resistance from these two values.

TG:HDL Ratio

The TG:HDL ratio identifies atherogenic dyslipidemia: elevated triglycerides driven by VLDL overproduction + low HDL reflecting impaired reverse cholesterol transport. TG:HDL ≥ 3.0–3.5 (men) or ≥ 2.5 (women) predicts insulin resistance with sensitivity ~79%, specificity ~74%.

Mechanistically: CETP mediates triglyceride enrichment of LDL and HDL → hepatic lipase hydrolyzes these → small dense LDL (most atherogenic LDL subtype).

HbA1c

HbA1c reflects integrated glycemic exposure over the 120-day erythrocyte lifespan. Risk gradient for cardiovascular complications begins well below the diabetic threshold (~5.6% / 38 mmol/mol). Advanced glycation end products (AGEs) from elevated glucose cross-link collagen in arterial walls → reduced compliance, systolic hypertension.

Confound: HbA1c can be falsely elevated in iron deficiency anemia (reduced RBC lifespan) or falsely normal despite glucose variability in altered RBC turnover states. Always interpret alongside fasting glucose and ideally CGM data.

Iron Metabolism (Ferritin + TSAT)

Iron catalyzes hydroxyl radical formation via the Fenton reaction — the mechanistic basis for its role in oxidative stress-mediated tissue damage. In the vasculature: iron-catalyzed ROS promotes LDL oxidation, endothelial dysfunction, and plaque destabilization.

Interpretation: Ferritin is both a storage protein AND an acute-phase reactant — elevated ferritin with elevated hs-CRP may be inflammatory hyperferritinemia, not true iron overload. TSAT (serum iron / TIBC × 100) is more specific for iron availability. Contextualize ferritin with hs-CRP.

Testing Protocol

Minimum Panel (Foundational)

• Lipid panel (expanded): TC, LDL-C, HDL-C, triglycerides, ApoB, lipoprotein(a), non-HDL-C
• Glycemic panel: Fasting glucose, fasting insulin, HbA1c, (ideally) CGM data
• Inflammatory panel: hs-CRP (high-sensitivity), twice ≥ 2 weeks apart
• Iron panel: Serum iron, ferritin, TSAT, TIBC

Conditions

• All blood work after 10–14 hour fast (water permitted)
• hs-CRP measured twice when clinically stable; average results
• Hold iron supplements 24–48h before iron studies if supplementing
• Avoid high-dose niacin, fish oil (>3g EPA+DHA), and alcohol 48h before lipid/triglyceride testing

Vitals-Specific Monitoring Cadence

Biomarker	First Retest	Subsequent Interval
ApoB, full lipid panel	8–12 weeks	Every 6 months if stable
hs-CRP	4–6 weeks	Every 3 months if elevated
Fasting insulin + glucose	8–12 weeks	Every 6 months
TG:HDL	8–12 weeks	Every 6 months
HbA1c	3–6 months	Every 6 months
Iron panel	3–6 months	Every 6–12 months

Related Notes

• Glycemic Variability — glucose fluctuation burden; CGM adds a dimension HbA1c misses
• Metabolic Flexibility — fuel-switching and return-to-baseline capacity
• Postprandial Glucose Response — meal-driven glucose peak and recovery
• HRV — autonomic state affects insulin sensitivity and vice versa
• Longevity Biomarkers Testing — epigenetic clocks, telomere attrition, SASP, IGF-1, Klotho for biological age assessment (complementary to this note)
• Rapamycin, Berberine, Urolithin A, Retatrutide — compounds with direct effects on these biomarker pathways